Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2139

3.
4.

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W.

Antivir Ther. 2004 Feb;9(1):57-65.

PMID:
15040537
5.

Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.

Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW.

Antimicrob Agents Chemother. 2004 Sep;48(9):3483-90.

6.

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.

Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 1999 Aug 20;13(12):1477-83.

PMID:
10465070
7.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

8.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
9.

Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques.

Pal R, Nuttall J, Galmin L, Weiss D, Chung HK, Romano J.

Virology. 2009 Mar 30;386(1):102-8. doi: 10.1016/j.virol.2009.01.002. Epub 2009 Feb 4.

11.

Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.

Isaka Y, Sato A, Kawauchi S, Suyama A, Miki S, Hayami M, Fujiwara T.

Microbiol Immunol. 1998;42(3):195-202.

12.

Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Uberla K, Stahl-Hennig C, Böttiger D, Mätz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B, et al.

Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8210-4.

13.

Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.

Rosenwirth B, ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K.

J Virol. 2000 Feb;74(4):1704-11.

14.

SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques.

Mandell CP, Reyes RA, Cho K, Sawai ET, Fang AL, Schmidt KA, Luciw PA.

Virology. 1999 Dec 20;265(2):235-51.

15.
16.

Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.

Tuaillon E, Gueudin M, Lemée V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1543-9.

PMID:
15577405
17.

In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.

Xu ZQ, Buckheit RW Jr, Stup TL, Flavin MT, Khilevich A, Rizzo JD, Lin L, Zembower DE.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2179-84.

PMID:
9873509
18.

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rösner M, Hughes SH, Arnold E.

J Mol Biol. 2001 Jun 1;309(2):437-45.

PMID:
11371163
19.

Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).

Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C.

Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7490-4.

Supplemental Content

Support Center